3 Exciting Biotechs Under $30: Zogenix's Drug Gives New Hope for Rare Indication
Dravet syndrome and Lennox-Gestaut syndrome are two rare forms of epilepsy that currently have no approved treatments, but Zogenix (NASDAQ: ZGNX) and GW Pharmaceuticals (NASDAQ: GWPH) are working to change that.
In this Industry Focus: Healthcare segment, Motley Fool analyst Kristine Harjes and contributor Todd Campbell explain how Zogenix's drug ZX008 works, why this is so exciting for patients and investors, some important things that investors should know about ZX008's history, and more.
A full transcript follows the video.
Source: Fool.com
